PRZOOM - /newswire/ -
Irvine, CA, United States, 2012/08/01 - MDxHealth SA, announced that the company’s Irvine, California, CLIA laboratory has received College of American Pathology (CAP) accreditation - MDxHealth.com. NYSE Euronext: MDXH
MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that the company’s Irvine, California, CLIA laboratory has received College of American Pathology (CAP) accreditation. CAP accreditation is an internationally recognized program established to improve patient safety by ensuring laboratories achieve the highest standards of excellence and exceed regulatory requirements. The first product offered through the Irvine laboratory is the company’s recently launched ConfirmMDxTM for Prostate Cancer test, which provides urologists with a DNA-based epigenetic assay to help distinguish patients who have a true-negative prostate biopsy from those who may have occult cancer.
“CAP accreditation is the gold standard for quality, and MDxHealth is committed to delivering high quality clinical diagnostic and pharmaceutical laboratory services that surpass regulatory requirements,” said Dr. Jan Groen, President and CEO of MDxHealth. “Our CLIA certified state-of-the-art facility is now fully accredited and licensed. Each day as our volumes for prostate cancer samples increases, quality and accuracy remain our priority.”
About the College of American Pathologists
The College of American Pathologists (CAP), celebrating 50 years as the gold standard of laboratory accreditation, is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the world’s largest association composed exclusively of Board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care. More information about the College can be found at cap.org.
MDxHealth (mdxhealth.com) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information.
For more information
Mike Sinclair, Halsin Partners
T: +44 20 7318 2955 / C: +44 7968 022075
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.